# US 2019/0376079 A1 · Compositions and methods for mammalian genetics and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0376079 A1
- Document ID: US20190376079A1
- Status: Published application
- Kind: A1
- Application number: 16/214,026
- Filed: 2018-12-07
- Published: 2019-12-12
- Earliest claimed: 2009-07-09
- Assignees: Whitehead Institute for Biomedical Research
- Applicants: Whitehead Institute for Biomedical Research
- Inventors: Thijn R. Brummelkamp; Jan E. Carette
- Web page: https://patentgrep.com/patent/US20190376079A1

## CPC

- C12N 15/86: Viral vectors
- C12N 15/1051: {Gene trapping, e.g. exon-, intron-, IRES-, signal sequence-trap cloning, trap vectors}
- C12N 15/1079: {Screening libraries by altering the phenotype or phenotypic trait of the host (reporter assays C12N15/1086)}
- C12N 2740/13043: viral genome or elements thereof as genetic vector
- C12N 2800/107: for mammalian
- C12N 2800/60: Vectors containing traps for, e.g. exons, promoters
- C12N 2840/44: being a specific part of the splice mechanism, e.g. donor, acceptor
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention provides compositions and methods for performing mammalian cell genetics, e.g., genetic screens, using near-haploid cells. The invention further provides genes and gene products isolated using the inventive methods and methods of use thereof.

## Claims

### Claim at position 1

-28. (canceled)

### Claim 29

A mammalian cancer cell engineered to express a set of reprogramming factors sufficient to reprogram a normal mammalian somatic cell to pluripotency.

### Claim 30 (depends on 29)

The mammalian cancer cell of claim 29, where the cell has been engineered to express Oct4, Sox2, Klf4, and c-Myc.

### Claim 31 (depends on 29)

The mammalian cancer cell of claim 29, where the cell is a hematopoietic cancer cell.

### Claim 32 (depends on 29)

The mammalian cancer cell of claim 29, where the cell is a human cancer cell.

### Claim 33 (depends on 29)

The mammalian cancer cell of claim 29, where the cell is a derivative of a KBM7 cell.

### Claim 34 (depends on 29)

A cell line comprising the mammalian cancer cell of claim 29, where the cell line is stable in culture for at least 10 passages.

### Claim 35

An adherent, near-haploid mammalian cell derived from a non-adherent near-haploid mammalian cell.

### Claim 36 (depends on 35)

The adherent, near-haploid mammalian cell of claim 35, wherein the cell is a derivative of a KBM7 cell.

### Claim at position 10

-49. (canceled)

### Claim 50

A method of identifying a gene that affects cell phenotype, the method comprising the steps of: (a) providing a library comprising adherent near-haploid mammalian cells in culture, wherein said adherent near-haploid mammalian cells are derived from a non-adherent near-haploid mammalian cell engineered to express a set of reprogramming factors, wherein at least some of said adherent near-haploid mammalian cells comprise a nucleic acid construct integrated into their genome, and wherein the nucleic acid construct comprises a nucleic acid that allows the identification of a cell containing said nucleic acid; (b) identifying a cell containing said nucleic acid construct integrated into its genome, wherein the cell exhibits a phenotype of interest; and (c) identifying a gene into which the nucleic acid construct integrated, thereby identifying a gene that affects cell phenotype.

### Claim 51 (depends on 50)

The method of claim 50, wherein the nucleic acid encodes a reporter that allows the identification of a cell expressing the nucleic acid.

### Claim 52 (depends on 50)

The method of claim 50, wherein the near-haploid mammalian cell is a human cell.

### Claim 53 (depends on 50)

The method of claim 50, wherein the adherent near-haploid mammalian cell is derived from a KBM7 cell.

### Claim 54 (depends on 50)

The method of claim 50, wherein the non-adherent near-haploid mammalian cell is genetically modified.

### Claim 55 (depends on 50)

The method of claim 50, wherein the nucleic acid construct comprises in operable association in a 5′ to 3 direction: (1) a splice acceptor site; (2) a nucleic acid encoding a reporter that allows the identification of a cell expressing the nucleic acid; and (3) a polyadenylation sequence.

### Claim 56 (depends on 55)

The method of claim 55, wherein the splice acceptor site is an adenoviral splice acceptor site.

### Claim 57 (depends on 50)

The method of claim 50, wherein the phenotype of interest is altered sensitivity to a compound of interest as compared with sensitivity of a suitable control cell to the compound of interest.

### Claim 58 (depends on 57)

The method of claim 57, wherein the compound of interest is a therapeutic agent.

### Claim 59 (depends on 50)

The method of claim 50, wherein step (b) comprises recovering and sequencing a portion of the gene.

### Claim 60 (depends on 50)

The method of claim 50, wherein the adherent near-haploid mammalian cell further comprises a reporter useful to identify cells having a phenotype of interest.

### Claim 61 (depends on 50)

The method of claim 50, wherein step (a) comprises introducing a gene trap vector into adherent near-haploid mammalian cells, wherein the gene trap vector comprises a nucleic acid construct comprising a nucleic acid encoding a reporter that allows the identification of cells expressing said nucleic acid, wherein said nucleic acid construct integrates into the genome of at least some of said adherent near-haploid mammalian cells; step (b) comprises identifying a plurality of cells containing said gene trap vector so integrated, wherein the cells exhibit a phenotype of interest; and step (c) comprises identifying a plurality of genes into which the nucleic acid construct integrated, thereby identifying a plurality of genes that affect cell phenotype.
